The Significance of Thrombocytosis Prior to Radiotherapy in Patients with Nasopharyngeal Carcinoma
Y Huang,T Lu,X Zeng,F Han,Y Sun
DOI: https://doi.org/10.1016/j.ijrobp.2005.07.636
2005-01-01
Abstract:Purpose/Objective: To explore the relationship between the survival rate, distant metastasis and thrombocytosis prior to radiotherapy with nasopharyngeal carcinoma. Materials/Methods: The data of 465 patients with nasopharyngeal carcinoma without metastasis who were treated with conventional radiation therapy alone between January 1998 and January 1999 at Cancer Center, Sun Yat-Sen University,Guangzhou in China were retrospectively analyzed. Platelet counts in peripheral blood were detected on all patients before radiotherapy, inter-treatment and after radiotherapy respectively. All patients (KPS≧70) were staged according to the 92 Fu Zhou of China TNM staging of nasopharyngeal carcinoma. The stage I, II, III and IV disease had 31,134, 226 and 74 cases, and T1, T2, T3, and T4 disease were 81,152,178 and 54 cases, and N0, N1, N2 and N3 disease were 156,169,115 and 25 cases respectively. There were 331 male and 134 female, male: female =2.47:1. The age ranged from 18 to 70 years (median, 46 years). All patients were delivered by the conventional external beam radiation alone. The fractionation dose was 2.0Gy/fraction/day, 5-fractions/week. The dose delivered to nasopharynx was 66Gy to 72Gy and that of cervical lymph nodes positive was 60Gy to 70Gy. And the prophylactic dose of neck negative was 46Gy to 54Gy. Thrombocytosis was defined as a platelet count exceeding 300×109/L. Results: 0ne hundred and thirty-eight of 465 (29.7%) nasopharyngeal carcinoma patients had thrombocytosis. Platelet count in patients with nasopharyngeal carcinoma were not associated with age and gender (P=0.408,P=0.343).Thrombocytosis was significantly more frequent in patients with advanced disease (stage III-IV) and positive lymph nodes(N1-3) (P=0.034, P=0.046). The overall survival rate of the 138 patients with thrombocytosis was significantly worse than that of the patients without thrombocytosis (59.6% VS 70.8%,P=0.036). The distant metastases rate was significantly higher in patients with thromocytosis than in those with a platelet count < 300×109/L (24% VS 12.5%, P=0.02). But it showed no statistically significant differences in the local-regional recurrence rate (P =0.421). The survival rate were calculated using the Kaplan-Merier method, and significance of survival curve differences calculated using the log-rank test. In multivariate analysis, the Cox proportional hazards model was used. The overall survival (OS), relapse-free survival rates (RFSR) and disease-free survival (DFS) for patients with versus those without thrombocytosis was 59.6% versus 70.8%, 84.1% versus 86.9%, and 61.9% versus 77.8% respectively (P = 0.036, P = 0.682, P = 0.008). In a multivariate analysis, thrombocytosis showed to be a predictor of worse prognosis. A multiple Cox regression model included gender, age, stage and pretreatment thrombocytosis,and showed pretreatment thrombocytosis as an independent risk factor for disease-free survival (DFS) (P =0.014). Conclusions: Platelet count changes in the patients with nasopharyngeal carcinoma were associated with TNM stages, but not with gender and age. Thrombocytosis were more frequent in patients with advanced disease (stage III-IVa) and positive lymph nodes. Pretreatment thrombocytosis is an independent risk factor for disease-free survival in patients with nasopharyngeal carcinoma. The distant metastases with nasopharyngeal carcinoma may be related to thrombocytosis.